{
  "timestamp": "2025-11-24T19:18:04.653846",
  "disease": "melanoma",
  "metrics": {
    "drug_ranking_accuracy": 0.5,
    "correct_predictions": 2,
    "total_predictions": 4,
    "average_confidence": 0.4
  },
  "target": {
    "drug_ranking_accuracy": 0.9,
    "average_confidence": 0.5
  },
  "results": [
    {
      "variant": "BRAF V600E",
      "expected_drug": "BRAF inhibitor",
      "expected_rank": 1,
      "expected_confidence": 0.4,
      "top_drug": "BRAF inhibitor",
      "top_confidence": 0.4,
      "evidence_tier": "consider",
      "drugs": [
        {
          "name": "BRAF inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.68,
          "evidence_tier": "consider"
        },
        {
          "name": "MEK inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.68,
          "evidence_tier": "consider"
        },
        {
          "name": "pembrolizumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "nivolumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "ipilimumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        }
      ],
      "correct": true,
      "mode": "full"
    },
    {
      "variant": "BRAF V600K",
      "expected_drug": "BRAF inhibitor",
      "expected_rank": 1,
      "expected_confidence": 0.4,
      "top_drug": "BRAF inhibitor",
      "top_confidence": 0.4,
      "evidence_tier": "consider",
      "drugs": [
        {
          "name": "BRAF inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.68,
          "evidence_tier": "consider"
        },
        {
          "name": "MEK inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.68,
          "evidence_tier": "consider"
        },
        {
          "name": "pembrolizumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "nivolumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "ipilimumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        }
      ],
      "correct": true,
      "mode": "full"
    },
    {
      "variant": "NRAS Q61R",
      "expected_drug": "MEK inhibitor",
      "expected_rank": 2,
      "expected_confidence": 0.4,
      "top_drug": "BRAF inhibitor",
      "top_confidence": 0.4,
      "evidence_tier": "consider",
      "drugs": [
        {
          "name": "BRAF inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.69,
          "evidence_tier": "consider"
        },
        {
          "name": "MEK inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.69,
          "evidence_tier": "consider"
        },
        {
          "name": "pembrolizumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "nivolumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "ipilimumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        }
      ],
      "correct": false,
      "mode": "full"
    },
    {
      "variant": "NRAS Q61K",
      "expected_drug": "MEK inhibitor",
      "expected_rank": 2,
      "expected_confidence": 0.4,
      "top_drug": "BRAF inhibitor",
      "top_confidence": 0.4,
      "evidence_tier": "consider",
      "drugs": [
        {
          "name": "BRAF inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.69,
          "evidence_tier": "consider"
        },
        {
          "name": "MEK inhibitor",
          "confidence": 0.4,
          "efficacy_score": 0.69,
          "evidence_tier": "consider"
        },
        {
          "name": "pembrolizumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "nivolumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        },
        {
          "name": "ipilimumab",
          "confidence": 0.4,
          "efficacy_score": 0.0,
          "evidence_tier": "insufficient"
        }
      ],
      "correct": false,
      "mode": "full"
    }
  ],
  "provenance": {
    "script": "benchmark_sota_melanoma.py",
    "api_base": "http://127.0.0.1:8000",
    "model_id": "evo2_1b",
    "ablation_mode": "SPE",
    "mode": "full"
  }
}